Larimar Therapeutics, Inc. (LRMR)

NASDAQ: LRMR · IEX Real-Time Price · USD

7.71

-0.53 (-6.43%)

At close: Jul 2, 2024, 4:00 PM

8.09

+0.38 (4.93%)

After-hours: Jul 2, 2024, 7:26 PM EDT

Larimar Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2011
Selling, General & Admin	14.09	12.28	12.07	11.4	2.42	Upgrade
Research & Development	27.67	24.25	38.4	31.41	20.79	Upgrade
Operating Expenses	41.76	36.53	50.47	42.8	23.21	Upgrade
Operating Income	-41.76	-36.53	-50.47	-42.8	-23.21	Upgrade
Other Expense / Income	-4.81	-1.17	0.17	-0.32	-0.08	Upgrade
Pretax Income	-36.95	-35.36	-50.64	-42.48	-23.13	Upgrade
Net Income	-36.95	-35.36	-50.64	-42.48	-23.13	Upgrade
Shares Outstanding (Basic)	44	26	17	12	6	Upgrade
Shares Outstanding (Diluted)	44	26	17	12	6	Upgrade
Shares Change	70.41%	50.09%	44.44%	95.09%	126.80%	Upgrade
EPS (Basic)	-0.84	-1.37	-2.95	-3.57	-3.80	Upgrade
EPS (Diluted)	-0.84	-1.37	-2.95	-3.57	-3.80	Upgrade
Free Cash Flow	-33.62	-27.67	-42.44	-42.26	-22.78	Upgrade
Free Cash Flow Per Share	-0.77	-1.07	-2.47	-3.56	-3.74	Upgrade
EBITDA	-36.72	-35.08	-50.3	-42.33	-23.05	Upgrade
Depreciation & Amortization	0.23	0.27	0.34	0.16	0.08	Upgrade
EBIT	-36.95	-35.36	-50.64	-42.48	-23.13	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).